Destiny Pharma Plc (DEST):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Destiny Pharma Plc (DEST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7967
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Destiny Pharma Plc (Destiny Pharma), formerly Destiny Pharma Ltd, a subsidiary of Destiny Pharma Holdings Ltd is a drug development and discovery company that offers commercial exploitation and clinical development of the antibacterial products. The company provides XF drug platform to address multi drug resistant microbial pathogens that cause infections. It offers clinical and preclinical assets for the treatment and prevention of bacterial infections. Destiny’s products find application in the treatment of lung infection, gram positive infection, gram negative infection and post surgical staphylococcal infection, among others. The company has its operations through a network of industry, governments and academia. Destiny is headquartered in Brighton, the UK.

Destiny Pharma Plc (DEST) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Destiny Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Destiny Pharma Raises More Than USD4.7 Million in Venture Financing 10
Partnerships 11
Destiny Pharma Enters into Research Agreement with Aston University 11
Destiny Pharma Enters into Agreement with China Medical System 12
Equity Offering 13
Destiny Pharma Raises USD2.4 Million in Private Placement of Shares 13
Destiny Pharma Raises USD19.8 Million in IPO 14
Destiny Pharma Plc – Key Competitors 15
Destiny Pharma Plc – Key Employees 16
Destiny Pharma Plc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Financial Announcements 18
Sep 26, 2018: Destiny Pharma: Interim results for the six months ended 30 June 2018 18
Sep 27, 2017: Destiny Pharma: Interim Results for the 6 Months Ended 30 June 2017 22
Corporate Communications 23
Sep 26, 2018: Destiny Pharma announces appointment of Chief Medical Officer 23
Sep 06, 2018: Destiny Pharma: Directorate Change 24
May 30, 2018: Destiny Pharma Establishes the Scientific Advisory Board 25
Apr 13, 2017: Destiny Pharma announces appointment of new CEO 27
Government and Public Interest 28
Jan 29, 2018: $1bn rewards proposed at Davos 2018 for new antibiotics 28
Other Significant Developments 29
Oct 19, 2018: Destiny Pharma: BIA celebrates UK bioscience in creating innovative new drugs and treatment for patients 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Destiny Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Destiny Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Destiny Pharma Raises More Than USD4.7 Million in Venture Financing 10
Destiny Pharma Enters into Research Agreement with Aston University 11
Destiny Pharma Enters into Agreement with China Medical System 12
Destiny Pharma Raises USD2.4 Million in Private Placement of Shares 13
Destiny Pharma Raises USD19.8 Million in IPO 14
Destiny Pharma Plc, Key Competitors 15
Destiny Pharma Plc, Key Employees 16

List of Figures
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Destiny Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Destiny Pharma Plc (DEST):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Siccar Point Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Siccar Point Energy Ltd (Siccar Point) is an oil and gas company that offers exploration and development of energy fields. The company acquires, and targets both operated and non-operated opportunities. Its exploration areas include Schiehallion field, Rosebank field, Suilven field, Cambo fi …
  • AXIS Capital Holdings Limited:戦略・SWOT・企業財務分析
    AXIS Capital Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary AXIS Capital Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Orica Limited:戦略・SWOT・企業財務分析
    Orica Limited - Strategy, SWOT and Corporate Finance Report Summary Orica Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • iNova Pharmaceuticals (Australia) Pty Ltd:企業の戦略的SWOT分析
    iNova Pharmaceuticals (Australia) Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Wolters Kluwer nv:企業の戦略・SWOT・財務分析
    Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report Summary Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Asarco LLC:企業の戦略・SWOT・財務分析
    Asarco LLC - Strategy, SWOT and Corporate Finance Report Summary Asarco LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Aslan Pharmaceuticals Pte Ltd:企業のM&A・事業提携・投資動向
    Aslan Pharmaceuticals Pte Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Aslan Pharmaceuticals Pte Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Cardiva Medical Inc:企業の戦略的SWOT分析
    Cardiva Medical Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Navistar International Corp (NAV):企業の財務・戦略的SWOT分析
    Navistar International Corp (NAV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Marubeni Power International Inc:電力:M&Aディール及び事業提携情報
    Summary Marubeni Power International Inc (Marubeni Power International), formerly National Power Development Inc, a subsidiary of Marubeni Corp, is an energy service provider that offers electricity generation and transmission services. The company acquires established power generation portfolios an …
  • G-III Apparel Group Ltd (GIII):企業の財務・戦略的SWOT分析
    Summary G-III Apparel Group, Ltd. (G-III or “the company”) is an apparel and footwear manufacturing company. The company designs, manufactures and markets outerwear, dresses, sportswear, swimwear, women's suits and performance wear, luggage, footwear, and women's handbags, leather goods, and cold we …
  • Octapharma AG:企業の戦略・SWOT・財務分析
    Octapharma AG - Strategy, SWOT and Corporate Finance Report Summary Octapharma AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Medherant Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Medherant Ltd (Medherant) is a transdermal drug delivery patch company. The company develops and commercializes novel technologies for delivery of drugs through the skin using expertise in bioadhesives and polymer chemistry to treat pain, Alzheimer's disease, and for smoking cessation, hormo …
  • Stellar Resources Ltd:企業の戦略・SWOT・財務分析
    Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fintel Energia Group SpA (FTL):企業の財務・戦略的SWOT分析
    Summary Fintel Energia Group SpA (Fintel) is a utility service provider that supplies electricity and natural gas. The company's services include designing, consultation, and installation of technologies and system of production of renewable energies for the Group and to third parties. It also provi …
  • Leap Therapeutics Inc (LPTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Leap Therapeutics Inc (Leap Therapeutics), formerly HealthCare Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with cancer. The company’s pipeline products include DKN-01, a humanized monoclonal antibody that targets the D …
  • Lario Oil & Gas Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Lario Oil & Gas Co (Lario Oil & Gas) is an oil and gas exploration and production company that explores and produces oil and gas properties. The company offers services such as discovering reserves organically from geologic thesis, drill-bit, field delineation, and land acquisition and explo …
  • Aldi Einkauf GmbH & Co oHG:企業の戦略・SWOT・財務分析
    Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report Summary Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ridley USA, Inc.:企業の戦略的SWOT分析
    Ridley USA, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆